Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
14.1M
-
Shares change
-
+63.2K
-
Total reported value, excl. options
-
$237M
-
Value change
-
+$1.24M
-
Put/Call ratio
-
0.96
-
Number of buys
-
36
-
Number of sells
-
-29
-
Price
-
$16.82
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2021
95 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q3 2021.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.1M shares
of 46.2M outstanding shares and own 30.46% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (2.95M shares), BlackRock Inc. (1.71M shares), CREDIT SUISSE AG/ (1.09M shares), RTW INVESTMENTS, LP (857K shares), GREAT POINT PARTNERS LLC (750K shares), ZEKE CAPITAL ADVISORS, LLC (724K shares), Migdal Insurance & Financial Holdings Ltd. (698K shares), Horton Capital Management, LLC (685K shares), Wildcat Capital Management, LLC (533K shares), and Clal Insurance Enterprises Holdings Ltd (529K shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.